<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02507765</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-15032</org_study_id>
    <secondary_id>NCI-2015-00894</secondary_id>
    <nct_id>NCT02507765</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Pilot Trial of Stereotactic Body Radiation Therapy (SBRT) to Induce Tumor Hyperemia in Combination With Transarterial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Varian Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies stereotactic body radiation therapy (SBRT) and
      transarterial chemoembolization (TACE) in treating patients with liver cancer that cannot be
      removed by surgery. SBRT is a specialized radiation therapy that delivers a high dose of
      radiation directly to the tumor and may kill more tumor cells and cause less damage to normal
      tissue. Chemoembolization kills tumor cells by carrying drugs directly into blood vessels
      near the tumors and then blocking the blood flow to allow a higher concentration of the drug
      to reach the tumor for a longer period of time. SBRT may make TACE more beneficial by
      increasing blood flow to the tumor, which may allow more of the TACE chemotherapy to enter
      the tumor. Giving SBRT with TACE may work better in treating patients with liver cancer that
      cannot be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To establish the feasibility of completing SBRT followed by TACE in a 2 day time period.

      SECONDARY OBJECTIVES:

      I. To determine acute tumor perfusion changes after SBRT using functional magnetic resonance
      imaging (MRI) (magnetic resonance [MR]-dynamic contrast enhanced [DCE]/perfusion weighted
      imaging [PWI], MR-diffusion, blood oxygen level dependent [BOLD] sequences).

      II. To establish safety and tolerability of this regimen. III. To determine overall response
      rates (using modified Response Evaluation Criteria in Solid Tumors [RECIST] criteria),
      including objective response rate (partial response [PR] + complete response [CR]) and
      clinical benefit rate (stable disease [SD] + PR + CR) at 1, 3, and 6 months after TACE.

      IV. To evaluate local control, progression-free survival, and overall survival at 1, 3, 6, 9,
      and 12 months after a single-dose of SBRT followed by TACE.

      V. To correlate micro ribonucleic acid (miRNA) biomarkers with response and toxicity.

      OUTLINE: This is a dose-escalation study of SBRT.

      Patients undergo SBRT on day 1 and TACE on day 2.

      After completion of study treatment, patients are followed up at 1-2 weeks and at 1, 3, 6, 9,
      12, 18, and 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">October 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of SBRT in combination with TACE, measured by the number of patients able to tolerate all study procedures</measure>
    <time_frame>2 days</time_frame>
    <description>Determined on the intent-to-treat principle. Any treatment delivery difficulties that arise that could impede successful delivery of this therapy sequence will be evaluated. The capability of the Ohio State University (OSU) system and communication between departments will be analyzed and deemed effective if it facilitates the successful treatment completion of all patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in diffusion</measure>
    <time_frame>Baseline to day 1 post-SBRT</time_frame>
    <description>Tested by comparing mean values pre- and post-SBRT using a paired t-test. Should there be concern for outliers, the median for each metric will be determined and compared using a corresponding non-parametric procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hypoxia measurements</measure>
    <time_frame>Baseline to day 1 post-SBRT</time_frame>
    <description>Tested by comparing mean values pre- and post-SBRT using a paired t-test. Should there be concern for outliers, the median for each metric will be determined and compared using a corresponding non-parametric procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perfusion</measure>
    <time_frame>Baseline to day 1 post-SBRT</time_frame>
    <description>Tested by comparing mean values pre- and post-SBRT using a paired t-test. Should there be concern for outliers, the median for each metric will be determined and compared using a corresponding non-parametric procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicities</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Includes measurement of grade 2-5 gastrointestinal symptoms, such as nausea, abdominal pain, hepatitis, enteritis, gastritis, bowel perforation, and fistula, as defined by Common Terminology Criteria for Adverse Events version 4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Calculated using standard clinical follow-up with MRI imaging and labs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (CR + PR) as measured by modified RECIST criteria version 1</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Calculated using standard clinical follow-up with MRI imaging and labs. Estimated using Kaplan-Meier analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Calculated using standard clinical follow-up with MRI imaging and labs. Estimated using Kaplan-Meier analysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in BOLD response to oxygen breathing based on T2 contrast induced by deoxyhemoglobin serving as an endogenous contrast agent</measure>
    <time_frame>Baseline to day 1 post-SBRT</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Kel (washout phase constant) values calculated from the DCE curve</measure>
    <time_frame>Baseline to day 1 post-SBRT</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in mean apparent diffusion coefficient generated from diffusion weighted images by using the b values</measure>
    <time_frame>Baseline to day 1 post-SBRT</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in miRNA expression</measure>
    <time_frame>Baseline to up to 3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in plateau signal intensity calculated from the DCE curve</measure>
    <time_frame>Baseline to day 1 post-SBRT</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Child-Pugh Class A</condition>
  <condition>Child-Pugh Class B</condition>
  <condition>Stage IIIA Hepatocellular Carcinoma</condition>
  <condition>Stage IIIB Hepatocellular Carcinoma</condition>
  <condition>Stage IIIC Hepatocellular Carcinoma</condition>
  <condition>Stage IVA Hepatocellular Carcinoma</condition>
  <condition>Stage IVB Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (SBRT, TACE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo SBRT on day 1 and TACE on day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (SBRT, TACE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <description>Undergo SBRT</description>
    <arm_group_label>Treatment (SBRT, TACE)</arm_group_label>
    <other_name>SBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transarterial Chemoembolization</intervention_name>
    <description>Undergo TACE</description>
    <arm_group_label>Treatment (SBRT, TACE)</arm_group_label>
    <other_name>TACE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a diagnosis of hepatocellular carcinoma by at least one criterion
             listed below:

               -  Histologically confirmed

               -  Magnetic resonance imaging (MRI) or computerized tomography (CT) findings
                  consistent with hepatocellular carcinoma

               -  Alpha fetoprotein (AFP) &gt; 400 ng/mL AND evidence of at least one solid liver
                  lesion &gt; 2 cm regardless of specific imaging characteristics on CT or MRI

          -  Patients must be non-transplantable, unresectable, or medically inoperable and
             eligible for TACE as determined by a multi-disciplinary team

          -  Absolute neutrophil count &gt;= 1.5 Ã— 10^9/L

          -  Hemoglobin &gt;= 9 g/dl

          -  Platelets &gt;= 50,000/mm^3

          -  Prothrombin time (PT)/international normalized ratio (INR) and activated partial
             thromboplastin time (PTTa) =&lt; 1.5

          -  Albumin &gt;= 2.5 g/dL

          -  Alkaline phosphatase &lt; 5 x upper limit of normal (ULN)

          -  Total bilirubin =&lt; 2.0 mg/dL

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 5 x ULN

          -  Creatinine =&lt; 1.5 mg/dL and calculated creatinine clearance &gt;= 60 mL/min or 24-hour
             urine creatinine clearance &gt;= 60 mL/min

          -  Must have Childs-Pugh A or B liver disease

          -  Patients must have no clinical signs of heart failure and meet New York Heart
             Association functional classification I or II defined as:

               -  Class I - patients with no limitation of activities; they suffer no symptoms from
                  ordinary activities

               -  Class II - patients with slight, mild limitation of activity; they are
                  comfortable with rest or with mild exertion

          -  Must have 1-3 liver lesions amenable to SBRT with tumor size &lt; 15 cm (single lesion or
             sum)

          -  Must be able to undergo two MRI scans, one before study treatment begins and another
             shortly after SBRT

          -  Patients with extrahepatic disease, portal hypertension, or bilobar disease are
             allowed

          -  Normal renal function (creatinine &lt; 1.5 mg/dL)

          -  Within 2 weeks of registration: patients must have vital signs, history/physical
             examination, laboratory studies (complete blood count [CBC] with differential,
             chemistries including liver function tests, AFP, creatinine clearance [CrCl]
             assessment, pregnancy test if needed)

          -  Life expectancy of at least 12 weeks in the opinion of investigator

          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Ability to provide written informed consent obtained prior to participation in the
             study and any related procedures being performed

          -  Women of child-bearing potential (WOCBP) must have a negative pregnancy test within 14
             days of the first administration of study treatment; urine human chorionic
             gonadotropin (HCG) is an acceptable pregnancy assessment

          -  Women/men of reproductive potential must be counseled on contraception/abstinence
             while receiving the study treatment

        Exclusion Criteria:

          -  Childs-Pugh C liver function

          -  Major liver vascular invasion

          -  Prior radiation to the liver or other upper abdominal regions

          -  Must not have any evidence of bleeding diathesis or active gastrointestinal bleeding

          -  Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder
             cancer, or carcinoma in situ of the cervix; patients with a previous malignancy
             without evidence of disease for &gt;= 3 years will be allowed to enter the trial

          -  History of active connective tissue disease (scleroderma)

          -  Subjects who are breast-feeding, or have a positive pregnancy test will be excluded
             from the study; should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her treating physician immediately

          -  Medical contraindication to MR imaging (e.g. pacemakers, metallic implants, aneurysm
             clips, known contrast allergy to gadolinium contrast, pregnancy, nursing mothers,
             weight greater than 350 pounds)

          -  Any serious and/or unstable pre-existing medical disorder (aside from malignancy
             exception above), psychiatric disorder, or other conditions that could interfere with
             subject's safety, obtaining informed consent or compliance to the study procedures, in
             the opinion of the investigator; this could include severe, active co-morbidities such
             as:

               -  Uncontrolled cardiac disease (hypertension, unstable angina, myocardial
                  infarction within last 6 months, uncontrolled congestive heart failure,
                  cardiomyopathy with decreased ejection fraction)

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at time of
                  registration

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy within 30 days of
                  registration

               -  Hepatic insufficiency resulting in jaundice and/or coagulation defects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terence Williams, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>The Ohio State University Comprehensive Cancer Center</last_name>
    <phone>800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence M. Williams, MD, PhD</last_name>
      <phone>614-293-5557</phone>
      <email>terence.williams@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Terence M. Williams, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2015</study_first_submitted>
  <study_first_submitted_qc>July 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Terence Williams</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>SBRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

